7.34
7.00%
+0.48
Fate Therapeutics Inc stock is currently priced at $7.34, with a 24-hour trading volume of 2.11M.
It has seen a +7.00% increased in the last 24 hours and a -1.61% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.89 pivot point. If it approaches the $7.34 resistance level, significant changes may occur.
Fate Therapeutics Inc Stock (FATE) Financials Data
Fate Therapeutics Inc (FATE) Revenue 2023
FATE reported a revenue (TTM) of $63.53 million for the quarter ending December 31, 2023, a -34.03% decline year-over-year.
Fate Therapeutics Inc (FATE) Net Income 2023
FATE net income (TTM) was -$160.93 million for the quarter ending December 31, 2023, a +42.88% increase year-over-year.
Fate Therapeutics Inc (FATE) Cash Flow 2023
FATE recorded a free cash flow (TTM) of -$138.42 million for the quarter ending December 31, 2023, a +51.22% increase year-over-year.
Fate Therapeutics Inc (FATE) Earnings per Share 2023
FATE earnings per share (TTM) was -$1.64 for the quarter ending December 31, 2023, a +43.64% growth year-over-year.
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
GlobeNewswire Inc.
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Benzinga
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Fate Therapeutics to Present at Upcoming March Investor Conferences
GlobeNewswire Inc.
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Benzinga
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):